
FDA grants AOC 1001 Fast Track Designation to treat Myotonic Dystrophy Type 1 (DM1).
AOC 1001, an investigational treatment for Myotonic Dystrophy Type 1 (DM1), a late-developing muscle disorder, has received fast track designation from the U.S. Food and Drug Administration (FDA). The ...